CNBC May 20, 2024
Key Points
– Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections.
– The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as drugs like Ozempic and Wegovy continue to skyrocket in popularity.
– Hims & Hers CEO Andrew Dudum told CNBC that the company is “confident” customers will be able to access a consistent supply of the compounded medications.
Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday.
Shares of the company jumped more than 30% Monday morning.
The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction...
Today's Sponsors
Today's Sponsor